SynthesisBMC cancer2026
Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to poly ADP-ribose polymerase (PARP) inhibitors limits durable clinical benefit in breast cancer. The translational relevance of resistance-associated genes to patient prognosis remains poorly characterized. This systematic review and meta-analysis evaluated the clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer.
methodsPubMed, Embase, and Web of Science were searched from January 2015 to April 2026 for studies reporting survival outcomes associated with PARP inhibitor resistance-associated or homologous recombination repair-related markers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup, sensitivity, and independent TCGA validation analyses.
resultsEighteen studies (13,641 patients) met inclusion criteria. Primary meta-analysis (five studies, n = 909) showed that HR repair axis positivity was associated with reduced mortality risk (HR = 0.508, 95% CI: 0.411-0.627, p < 0.0001; I
conclusionsHR repair axis positivity is associated with reduced mortality risk in breast cancer, independent of PARPi exposure. High PARP1 expression shows an inconclusive prognostic role. These findings support a conceptual distinction between functional HR deficiency and transcriptional biomarker overexpression. However, primary findings are based on limited studies (k = 5) and require prospective validation.
Indexed as
Identifiers
42458320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.